ArticleProceedings of the National Academy of Sciences of the United States of America2013
Predicting the public health benefit of vaccinating cattle against Escherichia coli O157.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 115 citations in OpenAlex.
- Prior pathogen exposure augments inter-individual heterogeneity in antibody levels and reinfection loads in a songbird-pathogen system.Scientific reports · 2026Article
- Developing a simple, cost-effective proof-of-concept vaccine candidate against EHEC for cattle.PloS one · 2026Article
- Reinfection with a Bacterial Pathogen Augments Heterogeneity in Host Disease Responses.Research square · 2025Article
- Article
- Alternatives to antibiotics for sustainable livestock production in the context of the One Health approach: tackling a common foe.Frontiers in veterinary science · 2025Review
- Devitalization of Bacteria in Composted Cattle Manure with Natural Additives and Risk for Environment.Life (Basel, Switzerland) · 2024Article
- Do asymptomatic STEC-long-term carriers need to be isolated or decolonized? New evidence from a community case study and concepts in favor of an individualized strategy.Frontiers in public health · 2024Article
- Enterohemorrhagic Escherichia coli O157:H7 antigens produced in transgenic lettuce effective as an oral vaccine in mice.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2023Article
- Prevalence of Shiga Toxin-ProducingAnimals : an open access journal from MDPI · 2023Article
- Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Safety and Immunogenicity of a Chimeric Subunit Vaccine against Shiga Toxin-ProducingInternational journal of molecular sciences · 2023Article
- ABToxins · 2022Review
- Prevalence and Epidemiology of Non-O157 Escherichia coli Serogroups O26, O103, O111, and O145 and Shiga Toxin Gene Carriage in Scottish Cattle, 2014-2015.Applied and environmental microbiology · 2021Article
- Article
- Shiga Toxin-Producing E. coli in Animals: Detection, Characterization, and Virulence Assessment.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Review
- The Role ofToxins · 2020Review
- Metabolic Traits of Bovine Shiga Toxin-ProducingToxins · 2020Article
- Genetic and Functional Analyses of Virulence Potential of anFrontiers in cellular and infection microbiology · 2020Article
- Shiga toxin sub-type 2a increases the efficiency of Escherichia coli O157 transmission between animals and restricts epithelial regeneration in bovine enteroids.PLoS pathogens · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 1 country.
Funding
Abstract
Identifying the major sources of risk in disease transmission is key to designing effective controls. However, understanding of transmission dynamics across species boundaries is typically poor, making the design and evaluation of controls particularly challenging for zoonotic pathogens. One such global pathogen is Escherichia coli O157, which causes a serious and sometimes fatal gastrointestinal illness. Cattle are the main reservoir for E. coli O157, and vaccines for cattle now exist. However, adoption of vaccines is being delayed by conflicting responsibilities of veterinary and public health agencies, economic drivers, and because clinical trials cannot easily test interventions across species boundaries, lack of information on the public health benefits. Here, we examine transmission risk across the cattle-human species boundary and show three key results. First, supershedding of the pathogen by cattle is associated with the genetic marker stx2. Second, by quantifying the link between shedding density in cattle and human risk, we show that only the relatively rare supershedding events contribute significantly to human risk. Third, we show that this finding has profound consequences for the public health benefits of the cattle vaccine. A naïve evaluation based on efficacy in cattle would suggest a 50% reduction in risk; however, because the vaccine targets the major source of human risk, we predict a reduction in human cases of nearly 85%. By accounting for nonlinearities in transmission across the human-animal interface, we show that adoption of these vaccines by the livestock industry could prevent substantial numbers of human E. coli O157 cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.